Last reviewed · How we verify

NCT03678064

Use of the LOK® Robotic Gait Trainer in the Early Rehabilitation of Children After an Acquired Brain Injury (ABI)

Completed NA Last updated 19 September 2024
What this trial tests

NA trial testing Lokomat in Injury, Brain in 7 participants. Completed in 15 March 2020.

Timeline
5 June 2018
Primary endpoint
15 March 2020
15 March 2020

Quick facts

Lead sponsorHolland Bloorview Kids Rehabilitation Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment7
Start date5 June 2018
Primary completion15 March 2020
Estimated completion15 March 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Holland Bloorview Kids Rehabilitation Hospital

Who can join

Adults 5 to 18, any sex, with Injury, Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After an acquired brain injury (ABI), children often require extensive physiotherapy (PT) to help them relearn to walk. There is promising evidence in pediatric neuro-motor conditions of the possibility for brain activation pattern changes in response to repetitive, task-oriented functional gait training. Robotic-assisted gait training devices such as the Lokomat (LOK) allow this type of intensive walking retraining. The aim of this study is to assess the safety, feasibility and outcome possibilities linked to a LOK intervention given as 2 of the child's 4 PT weekly sessions over 8-weeks in the early stages of rehabilitation after an ABI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lokomat

Trials testing the same drug.

Other Holland Bloorview Kids Rehabilitation Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03678064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing